0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Raynaud's Phenomenon: A Common Toxicity After Combination Chemotherapy for Testicular Cancer

NICHOLAS J. VOGELZANG, M.D.; GEORGE J. BOSL, M.D.; KAY JOHNSON, R.N.; and B.J. KENNEDY, M.D.
[+] Article and Author Information

Grant support: in part by the United States Public Health Service grant CA-19527, National Cancer Institute; grant CF-4308A, the American Cancer Society; the Whirlpool Foundation; the Minnesota Medical Foundation; and the Masonic Memorial Hospital Fund, Inc.

Dr. Bosl's current affiliation is Assistant Attending Physician, Solid Tumor Service, Memorial Hospital, New York, New York.

▸Requests for reprints should be addressed to Nicholas J. Vogelzang, M.D.; Box 286, University of Minnesota Hospitals; Minneapolis, MN 55455.


Minneapolis, Minnesota


© 1981 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1981;95(3):288-292. doi:10.7326/0003-4819-95-3-288
Text Size: A A A

Raynaud's phenomenon occurred in 22 of 60 men (37%) treated with vinblastine and bleomycin with or without cisplatin for germ cell testicular cancer. An additional six patients (10%) had symptoms suggestive of Raynaud's phenomenon. Patients with and without Raynaud's phenomenon did not differ with respect to median age; tumor histology; total doses of vinblastine, bleomycin, and cisplatin; or the frequency of vinblastine-induced neuropathy and bleomycin-induced cutaneous toxicity. Digital ischemia occurred in 21% of patients treated with only vinblastine and bleomycin, and in 41% of patients treated also with cisplatin. Cigarette smoking was commoner in patients with than in those without Raynaud's phenomenon. Hand arteriograms showed diffuse arterial narrowing and abrupt vascular cutoffs. Except for one patient with a very low titer of cold agglutinins, no patient had detectable antinuclear antibody, rheumatoid factor, cryoglobulins, or cold agglutinins. Raynaud's phenomenon is a common delayed toxicity after chemotherapy with vinblastine, bleomycin, and cisplatin in patients with germ cell neoplasms.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)